Core Viewpoint - The company, Chaoyujian Ophthalmology (02219), announced a share buyback plan to repurchase up to HKD 50 million worth of its shares starting from November 17, 2025, following approval from shareholders at the annual general meeting on June 6, 2025 [1] Group 1 - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - The board may increase the maximum buyback amount based on market conditions, with timely announcements made as necessary according to listing rules [1] - The company asserts that its current financial resources are sufficient to implement the share buyback while maintaining a robust financial position [1]
朝聚眼科(02219)拟购回最多价值5000万港元的公司股份